Related Experiment Video

Updated: Jan 11, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.2K

FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2

Hinano Nishikubo1, Dongheng Ma1, Tomoya Sano1

  • 1Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.

International Journal of Molecular Sciences
|November 13, 2025
PubMed

Insights

Fibroblast growth factor receptor 2 (FGFR2) gene abnormalities are found in various cancers. FGFR2 inhibitors show promise beyond cholangiocarcinoma, particularly in esophagus/stomach and breast cancers with FGFR2 alterations.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Genetic abnormalities in fibroblast growth factor receptor 2 (FGFR2), including amplification, fusions, and mutations, are implicated in diverse solid tumors.
  • While FGFR2 fusions are targeted in cholangiocarcinoma, the efficacy of FGFR2 inhibitors in other solid cancers remains under investigation.

Purpose of the Study:

  • To investigate the clinical-pathological significance of FGFR2 gene abnormalities in solid tumors using a large-scale Japanese database.
  • To explore the therapeutic potential of FGFR2 inhibitors in cancers beyond cholangiocarcinoma.

Main Methods:

  • Analysis of genomic and clinical data from 101,231 solid tumor patients in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database.
  • Identification and characterization of FGFR2 alterations (amplification, fusion, mutation) in 1312 patients.
  • Evaluation of treatment outcomes for 85 patients receiving FGFR2 inhibitors.

Main Results:

  • FGFR2 abnormalities were identified in 1312 out of 101,231 patients, with alterations including amplification (515), fusion (280), and mutation (568).
  • The most frequent sites for FGFR2 alterations were the biliary tract (271), esophagus/stomach (231), and breast (211).
  • Disease control was achieved in 49 of 85 patients treated with FGFR2 inhibitors, with 44 cases being biliary tract cancer.

Conclusions:

  • FGFR2 alterations are prevalent across various solid tumors, with distinct patterns of amplification and mutation.
  • FGFR2 inhibitors demonstrate therapeutic potential in biliary tract cancer and suggest promise for esophagus/stomach and breast cancers harboring FGFR2 alterations.
Keywords:
FGFR2fusiongene alterationssolid tumortherapeutic target

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K